A comparative study of Dr. Rainer's Vaginal Cream and Monistat Vaginal Cream for the treatment of vaginal candiasis.

A comparative study of Vagi Relief Vaginal Cream and Monistat Vaginal Cream for the treatment of vaginal candiasis.

 Amir Marashi, MD; Asif Luqman, MD

Introduction:

Candida albicans is a fungus that is normally present on the skin and in mucous membranes such as the vagina, mouth, or rectum. It is an opportunistic organism and given the right environment, it can thrive and lead to what is commonly known as a yeast infection. As per the CDC recommendations, there are over 12 different treatment regimens that can be used to treat Candida albicans vulvovaginitis. In this clinical study, our objective is to see how a new over the counter medication, Vagi Relief Vaginal Cream, compares to one of the standard treatments used, Monistat Cream.

 

Methods and materials:

This study was performed with patients ranging from 18-60 years old, each with documented vaginal pruritis/ visual yeast like discharge on speculum diagnostic of vulvovaginal candida. Our study participants were divided into two groups. Group A was given Vagi Relief, group B was given Monistat. Patients were then telephoned after 10 days with a verbal survey with regards to outcome of vulvar discharge/ pruritis, and completion of course of treatment.

 

Data:    

	Symptom Relief	Completion of course	Would you use Vagi Relief again?
Yes	15	16	15
No	2	1	2

 

Conclusion:

From the above data it can be seen that of the 17 women who were given Vagi Relief, 16 of them completed the course of treatment as recommended. The one patient who did not complete the treatment course states that she did not see changes to her symptoms soon enough and consequently discontinued the treatment. Of the 16 patients that completed the treatment, 15 found that their symptoms were relieved and all 15 of these patients stated that they would use Vagi Relief again. There was one patient that did not feel her symptoms were relieved by Vagi Relief despite completion of treatment course. She did, however, state that her symptoms did not worsen. Only 5.8% of patients found no changes in the symptoms even with completion of the prescribed Vagi Relief treatment course. A total of 88% of the patients found relief from vulvovaginal candidiasis while using Vagi Relief. However, if taking into account compliance with course of treatment that number increases to 94%. Hence, in conclusion, this study suggests that Vagi Relief has a cure rate of vaginal candiasis (vaginal yeast infection) of 94%.